Dr. Mona Rady | Education and Research | Best Researcher Award

Dr. Mona Rady | Education and Research | Best Researcher Award

German University in Cairo (GUC) and German International University (GIU) | Egypt

Dr. Mona Rady, PhD, is a Lecturer in Microbiology, Immunology, and Biotechnology at the German University in Cairo (GUC) and the German International University (GIU), with over 19 years of teaching and research experience. She earned her PhD in Microbiology and Immunology from GUC in 2014, following an MSc in Pharmacology and Toxicology (2009) and a BSc in Pharmaceutical Sciences from Ain Shams University (2002). She recently completed an MSc in Public Health at the University of South Wales, UK (2023). Her research interests focus on cancer immunology, natural killer (NK) cell epitranscriptomics, immune modulation, immunotherapy, microbiome–immune interactions, and RNA modifications such as m6A. She has supervised numerous PhD, MSc, and BSc theses, and her publication record reflects impactful contributions to NK cell biology and cancer immunology, with 7 documents, 179 citations, and an h-index of 7 on Google Scholar. Dr. Rady has received prestigious grants and fellowships including GERF-STDF, ASRT-BA, DAAD-GERSS, and Nature Publishing Group awards. She also serves as reviewer for journals such as Frontiers in Oncology and Immunology and Cell Biology. Through her multidisciplinary expertise, leadership in curriculum development, and international collaborations, Dr. Rady has established herself as a dedicated scientist advancing immunological research and education.

Profile: ORCID | Google Scholar

Featured Publications

 “Ginkgo biloba extract (EGb 761) mitigates methotrexate-induced testicular insult in rats: Targeting oxidative stress, energy deficit and spermatogenesis”

“The role of protein interaction domains in the human cancer network”

“Impact of N6-methyladenosine (m6A) modification on immunity”

“Pioglitazone attenuates lipopolysaccharide-induced oxidative stress, dopaminergic neuronal loss and neurobehavioral impairment by activating Nrf2/ARE/HO-1”

“Expression of RFC/SLC19A1 is associated with tumor type in bladder cancer patients”

“Altered expression of miR-181a and miR-146a does not change the expression of surface NCRs in human NK cells”

“Extracellular vesicles: from intracellular trafficking molecules to fully fortified delivery vehicles for cancer therapeutics”

Mrs. Shradha Sinha | Endocrinology | Best Researcher Award

Mrs. Shradha Sinha | Endocrinology | Best Researcher Award

Central Drug Research Institute | India

Author Profile

Scopus

Early Academic Pursuits

Shradha Sinha’s academic journey reflects a solid foundation in the life sciences, particularly in zoology, with a deepening interest in biomedical research. Her formative education laid the groundwork for her specialization in musculoskeletal biology, where she honed her understanding of complex biological systems. Driven by scientific curiosity and the desire to make a tangible impact in health-related fields, she excelled in competitive national-level examinations such as the CSIR-NET Junior Research Fellowship and the GATE Life Sciences assessment. These academic milestones not only validated her expertise but also opened doors to high-quality research opportunities. From the outset, her academic inclinations were clearly aligned with solving real-world health challenges through biological research.

Professional Endeavors

Currently serving as a Senior Research Fellow at the Central Drug Research Institute, Shradha Sinha plays a key role in advancing preclinical and translational research related to bone health and osteoarthritis. Her professional path demonstrates a seamless progression from academic training to applied biomedical research. Within her institutional role, she has taken on increasingly complex projects, collaborating across disciplines and managing multifaceted experimental designs. Her contributions to scientific inquiry are not limited to routine bench work but extend to the conception, execution, and dissemination of research projects with therapeutic relevance. Shradha’s ability to translate conceptual frameworks into data-driven discoveries showcases her as a well-rounded professional within the biomedical sciences.

Contributions and Research Focus

Shradha’s research contributions are situated at the intersection of bone biology, nutraceuticals, and pharmacological innovation. Her body of work reflects a dual focus on natural product-based therapeutics and synthetic pharmacological agents for skeletal diseases, particularly osteoporosis and osteoarthritis. One of her noteworthy projects involved evaluating the flavonoid content of banana pulp and peel and assessing their role in bone regeneration. This study provided novel evidence supporting the use of banana-derived compounds in mitigating bone loss and enhancing osteoblast differentiation—paving the way for low-cost, dietary-based interventions in bone health. Published in a high-impact journal, this work demonstrates both scientific rigor and translational potential.

In a separate but complementary study, she investigated the effects of a kappa-opioid receptor agonist (U50,488H) in the context of osteoarthritis. Her findings revealed that this agent could reduce cartilage degradation, inhibit chondrocyte hypertrophy, and prevent bone loss—adding a pharmacological dimension to her research portfolio. Together, these projects underscore her commitment to advancing therapeutic strategies through both natural and synthetic avenues, addressing the burden of degenerative bone diseases with a multifaceted approach. Additionally, her contributions include 11 peer-reviewed publications, a book chapter, and a patent, reflecting both productivity and innovation in her research output.

Accolades and Recognition

Although still in the early phase of her career, Shradha has already distinguished herself through her research productivity and academic excellence. Her success in securing nationally competitive fellowships and authoring high-quality publications signals her standing within the scientific community. The publication of her work in reputed journals, as well as her involvement in patented innovations, points to the recognition she has garnered for the originality and relevance of her work. Her interdisciplinary research has received commendation not only from peers but also from institutional mentors and collaborators. These accolades reflect her potential to emerge as a leading figure in musculoskeletal research in the years ahead.

Impact and Influence

Shradha’s research is poised to make a significant impact in both scientific and public health domains. Her exploration of nutraceuticals aligns well with growing global interest in functional foods and natural therapies for chronic conditions. By investigating the therapeutic roles of readily available substances like banana peel extracts, she is contributing to the development of cost-effective solutions that may benefit populations with limited access to conventional medicine. Her work with opioid receptor agonists also addresses a major gap in osteoarthritis management, offering promising insights into non-traditional pathways for intervention. Collectively, her contributions are bridging gaps between laboratory discoveries and real-world applications, enhancing the relevance of biomedical science to broader societal needs.

Legacy and Future Contributions

Looking ahead, Shradha Sinha is well-positioned to expand her influence in biomedical research, particularly in the area of skeletal health. Her ongoing commitment to investigating novel therapeutic agents and her interdisciplinary approach suggest a promising trajectory. As she continues to publish, patent, and collaborate, her work is likely to inform clinical practices and shape future therapeutic strategies. Moreover, her early career success serves as an inspiration for aspiring researchers, especially women in science, who look to combine academic excellence with social impact. Her legacy will likely be defined not only by the quality of her research but also by her dedication to innovation, mentorship, and translational science.

Notable Publications

U50 488H KOR agonist reduces cartilage degradation, chondrocyte hypertrophy and bone loss in osteoarthritis

Authors: Shradha Sinha; Anirban Sardar; Shikha Verma; Geeta Dhaniya; Ritu Trivedi

Journal: International Immunopharmacology

Year: 2025